Inotuzumab ozogamicin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD22 |
| Clinical data | |
| Trade names | Besponsa |
| Other names | CMC-544 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617041 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 97% (cytotoxic agent) |
| Elimination half-life | 12.3 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10002N1738O2036S42 |
| Molar mass | 146634.36 g·mol−1 |
| (what is this?) (verify) | |
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).[3][4] It is administered by intravenous infusion.[3][4][5]
Inotuzumab ozogamicin consists of a humanized monoclonal antibody against CD22 (inotuzumab), linked to a cytotoxic agent from the class of calicheamicins called ozogamicin.[6]
The US Food and Drug Administration considers it to be a first-in-class medication.[7]
- ^ "Regulatory Decision Summary for Besponsa". 23 October 2014.
- ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ a b c "Besponsa 1 mg powder for concentrate for solution for infusion". UK Electronic Medicines Compendium. June 2017. Retrieved 19 August 2017.
- ^ a b c "Besponsa- inotuzumab ozogamicin injection, powder, lyophilized, for solution". DailyMed. 15 September 2020. Retrieved 16 November 2020.
- ^ Jabbour EJ, Rousselot P, Gokbuget N, Chevallier P, Kantarjian HM, Stelljes M (January 2025). "Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic Leukemia". Clinical Lymphoma, Myeloma & Leukemia. 25 (5): e302 – e309. doi:10.1016/j.clml.2024.12.016. PMID 39909815.
- ^ Ricart AD (October 2011). "Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin". Clinical Cancer Research. 17 (20): 6417–6427. doi:10.1158/1078-0432.ccr-11-0486. PMID 22003069.
- ^ New Drug Therapy Approvals 2017. U.S. Food and Drug Administration (FDA) (Report). January 2018. Archived from the original (PDF) on 14 September 2019. Retrieved 16 September 2020.